Monthly
US$200
Billed every month
Levofloxacin Eye Drops(左氧氟沙星滴眼液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationAccepted: 4 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders1View records ↓
Under-review filings16View records ↓
This year’s generic filers8View records ↓
NHSA approval numbers55View records ↓
API companies with A status51View records ↓
Chemical-drug catalogue
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Santen Pharmaceutical Co.,Ltd. | Santen Pharmaceutical Co., Ltd. 应该为Santen Pharmaceutical Co., Ltd.Noto Plant | H20150278 | 2004/11/15 | 5ml:24.4mg | Imported originator drug (进口原研药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 55 distinct approval numbers and 47 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广东南国药业有限公司 | 国药准字H20264249 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010100315 | NHSA |
| 汕头经济特区明治医药有限公司 | 国药准字H20234675 | 0.488%(5ml:24.4mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010100547 | NHSA |
| 广州大光制药有限公司 | 国药准字H20233723 | 0.488%(5ml:24.4mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010100548 | NHSA |
| 珠海亿胜生物制药有限公司 | 国药准字H20183227 | 0.4ml:1.952mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010100612 | NHSA |
| 沈阳兴齐眼药股份有限公司 | 国药准字H20203593 | 0.4ml:1.952mg(以C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010101322 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20103148 | 0.488%(5ml:24.4mg,(以C18H20FN3O4计)) | Category A (甲) | XS01AEZ074G010010101442 | NHSA |
| 江苏万高药业股份有限公司 | 国药准字H20253857 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010101503 | NHSA |
| 苏州弘森药业股份有限公司 | 国药准字H20243939 | 0.488%(0.3ml:1.464mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010101518 | NHSA |
| 苏州乐珠制药有限公司 | 国药准字H20173405 | 0.488%(5ml:24.4mg,以C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010101652 | NHSA |
| 扬子江药业集团有限公司 | 国药准字H20203092 | 5ml:24.4mg(以C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010101749 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20183382 | 5ml:24.4mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010101955 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20249743 | 0.488%(0.6ml∶2.928mg,按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010101967 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20203457 | 5ml:24.4mg(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010102087 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20093808 | 5ml:24.4mg(以C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010102138 | NHSA |
| 河北创健药业有限公司 | 国药准字H20113118 | 5ml:24.4mg(以左氧氟沙星计) | Category A (甲) | XS01AEZ074G010010102680 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20233998 | 0.488%(5ml:24.4mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010102733 | NHSA |
| 石家庄四药有限公司 | 国药准字H20256148 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010102763 | NHSA |
| 吉林敖东药业集团延吉股份有限公司 | 国药准字H20244930 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010103358 | NHSA |
| 吉林省西点药业科技发展股份有限公司 | 国药准字H20254737 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010103454 | NHSA |
| 安徽环球药业股份有限公司 | 国药准字H20243616 | 规格:0.488%(5ml:24.4mg)(按C18H20FN3 | Category A (甲) | XS01AEZ074G010010104303 | NHSA |
| 合肥利民制药有限公司 | 国药准字H20254640 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010104423 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20234661 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010104693 | NHSA |
| 福建天泉药业股份有限公司 | 国药准字H20265172 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010104817 | NHSA |
| 云南傣药有限公司 | 国药准字H20244929 | 0.488%(5ml:24.4㎎)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010105619 | NHSA |
| 海南斯达制药有限公司 | 国药准字H20263023 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010105816 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字J20150106 | 5ml:24.4mg | Category A (甲) | XS01AEZ074G010010109591 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20203122 | 5ml:24.4mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010109920 | NHSA |
| 亚邦医药股份有限公司 | 国药准字H20254733 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010110144 | NHSA |
| 山东光明药业有限公司 | 国药准字H20243581 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010180494 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20203500 | 5ml:24.4mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010181567 | NHSA |
| 深圳市瑞霖医药有限公司 | 国药准字H20213721 | 5ml:24.4mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010183060 | NHSA |
| 石家庄凯赛医药科技有限公司 | 国药准字H20249227 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010183164 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254169 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010183191 | NHSA |
| 山东博士伦福瑞达制药有限公司 | 国药准字H20223131 | 0.488%(0.4ml:1.952mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010183223 | NHSA |
| 艾视制药有限公司 | 国药准字H20234223 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010183549 | NHSA |
| 苏州欧康维视生物科技有限公司 | 国药准字H20244928 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010183562 | NHSA |
| 上海阿尔福斯医药科技有限公司 | 国药准字H20249567 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010184738 | NHSA |
| 润尔眼科药物(广州)有限公司 | 国药准字H20263115 | 0.488%(5ml:24.4mg,按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010184784 | NHSA |
| 河北义海医药科技有限公司 | 国药准字H20263582 | 0.488%(0.4ml∶1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010185039 | NHSA |
| 安徽康融药业有限公司 | 国药准字H20264702 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010185072 | NHSA |
| 广州大光制药有限公司 | 国药准字H20233723 | 0.488%(5ml:24.4mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010200548 | NHSA |
| 珠海亿胜生物制药有限公司 | 国药准字H20183227 | 0.4ml:1.952mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010200612 | NHSA |
| 沈阳兴齐眼药股份有限公司 | 国药准字H20203593 | 0.4ml:1.952mg(以C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010201322 | NHSA |
| 苏州弘森药业股份有限公司 | 国药准字H20243939 | 0.488%(0.3ml:1.464mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010201518 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20249743 | 0.488%(0.6ml∶2.928mg,按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010201967 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20233998 | 0.488%(5ml:24.4mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010202733 | NHSA |
| 吉林敖东药业集团延吉股份有限公司 | 国药准字H20244930 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010203358 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20234661 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010204693 | NHSA |
| 海南斯达制药有限公司 | 国药准字H20263023 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010205816 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ20150278 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010278986 | NHSA |
| 山东光明药业有限公司 | 国药准字H20243581 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010280494 | NHSA |
| 山东辰欣佛都药业股份有限公司 | 国药准字H20254169 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010283191 | NHSA |
| 上海阿尔福斯医药科技有限公司 | 国药准字H20249567 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010284738 | NHSA |
| 珠海亿胜生物制药有限公司 | 国药准字H20183227 | 0.4ml:1.952mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010010300612 | NHSA |
| 湖北远大天天明制药有限公司 | 国药准字H20249743 | 0.488%(0.6ml∶2.928mg,按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010301967 | NHSA |
| 吉林敖东药业集团延吉股份有限公司 | 国药准字H20244930 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010303358 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20234661 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010304693 | NHSA |
| 海南斯达制药有限公司 | 国药准字H20263023 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010305816 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ20150278 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010378986 | NHSA |
| 上海阿尔福斯医药科技有限公司 | 国药准字H20249567 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010384738 | NHSA |
| 吉林敖东药业集团延吉股份有限公司 | 国药准字H20244930 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010403358 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20234661 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010404693 | NHSA |
| 上海阿尔福斯医药科技有限公司 | 国药准字H20249567 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010484738 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20234661 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010504693 | NHSA |
| 上海阿尔福斯医药科技有限公司 | 国药准字H20249567 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010010584738 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20234661 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010604693 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20234661 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010704693 | NHSA |
| 浙江莎普爱思药业股份有限公司 | 国药准字H20234661 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010010804693 | NHSA |
| 沈阳兴齐眼药股份有限公司 | 国药准字H20217093 | 5ml∶24.4mg(以C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020101322 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20103148 | 0.488%(5ml:24.4mg,(以C18H20FN3O4计)) | Category A (甲) | XS01AEZ074G010020101442 | NHSA |
| 苏州弘森药业股份有限公司 | 国药准字H20243939 | 0.488%(0.3ml:1.464mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020101518 | NHSA |
| 武汉诺安药业有限公司 | 国药准字H20223058 | 0.488%(5ml:24.4mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020101955 | NHSA |
| 河北创健药业有限公司 | 国药准字H20113118 | 5ml:24.4mg(以左氧氟沙星计) | Category A (甲) | XS01AEZ074G010020102680 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20247322 | 0.488%(0.6ml:2.928mg) (按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020102733 | NHSA |
| 参天制药(中国)有限公司 | 国药准字H20205052 | 0.488%(5ml:24.4mg)(按C18H20FN304计) | Category A (甲) | XS01AEZ074G010020109591 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20203122 | 5ml:24.4mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020109920 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20217124 | 0.3ml﹕1.464mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020181567 | NHSA |
| 山东福瑞达医药集团有限公司 | 国药准字H20223033 | 0.488%(0.6ml∶2.928mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020183060 | NHSA |
| 艾视制药有限公司 | 国药准字H20234222 | 0.488%(0.4ml:1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020183549 | NHSA |
| 苏州欧康维视生物科技有限公司 | 国药准字H20249151 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄ 计) | Category A (甲) | XS01AEZ074G010020183562 | NHSA |
| 河北义海医药科技有限公司 | 国药准字H20263582 | 0.488%(0.4ml∶1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020185039 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20247322 | 0.488%(0.6ml:2.928mg) (按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020202733 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20217124 | 0.3ml﹕1.464mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020281567 | NHSA |
| 山东福瑞达医药集团有限公司 | 国药准字H20223033 | 0.488%(0.6ml∶2.928mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020283060 | NHSA |
| 河北义海医药科技有限公司 | 国药准字H20263582 | 0.488%(0.4ml∶1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020285039 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20247322 | 0.488%(0.6ml:2.928mg) (按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020302733 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20217124 | 0.3ml﹕1.464mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020381567 | NHSA |
| 山东福瑞达医药集团有限公司 | 国药准字H20223033 | 0.488%(0.6ml∶2.928mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020383060 | NHSA |
| 河北义海医药科技有限公司 | 国药准字H20263582 | 0.488%(0.4ml∶1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020385039 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20247322 | 0.488%(0.6ml:2.928mg) (按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020402733 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20217124 | 0.3ml﹕1.464mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020481567 | NHSA |
| 山东福瑞达医药集团有限公司 | 国药准字H20223033 | 0.488%(0.6ml∶2.928mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020483060 | NHSA |
| 河北义海医药科技有限公司 | 国药准字H20263582 | 0.488%(0.4ml∶1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020485039 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20247322 | 0.488%(0.6ml:2.928mg) (按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020502733 | NHSA |
| 四川禾亿制药有限公司 | 国药准字H20217124 | 0.3ml﹕1.464mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020581567 | NHSA |
| 山东福瑞达医药集团有限公司 | 国药准字H20223033 | 0.488%(0.6ml∶2.928mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020583060 | NHSA |
| 石家庄格瑞药业有限公司 | 国药准字H20247322 | 0.488%(0.6ml:2.928mg) (按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010020602733 | NHSA |
| 山东福瑞达医药集团有限公司 | 国药准字H20223033 | 0.488%(0.6ml∶2.928mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010020683060 | NHSA |
| 珠海联邦制药股份有限公司中山分公司 | 国药准字H20256135 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010030100600 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20103148 | 0.488%(5ml:24.4mg,(以C18H20FN3O4计)) | Category A (甲) | XS01AEZ074G010030101442 | NHSA |
| 成都普什制药有限公司 | 国药准字H20233516 | 0.488%(0.3ml:1.464mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010030102298 | NHSA |
| 河北创健药业有限公司 | 国药准字H20113118 | 5ml:24.4mg(以左氧氟沙星计) | Category A (甲) | XS01AEZ074G010030102680 | NHSA |
| 宁夏康亚药业股份有限公司 | 国药准字H20223509 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010030105911 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20203122 | 5ml:24.4mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010030109920 | NHSA |
| 河北义海医药科技有限公司 | 国药准字H20263582 | 0.488%(0.4ml∶1.952mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010030185039 | NHSA |
| 成都普什制药有限公司 | 国药准字H20233516 | 0.488%(0.3ml:1.464mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010030202298 | NHSA |
| 成都普什制药有限公司 | 国药准字H20233516 | 0.488%(0.3ml:1.464mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010030302298 | NHSA |
| 成都普什制药有限公司 | 国药准字H20233516 | 0.488%(0.3ml:1.464mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010030402298 | NHSA |
| 成都普什制药有限公司 | 国药准字H20233516 | 0.488%(0.3ml:1.464mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010030502298 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20103148 | 0.488%(5ml:24.4mg,(以C18H20FN3O4计)) | Category A (甲) | XS01AEZ074G010040101442 | NHSA |
| 河北创健药业有限公司 | 国药准字H20113118 | 5ml:24.4mg(以左氧氟沙星计) | Category A (甲) | XS01AEZ074G010040102680 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20247102 | 0.488%(0.4ml:1.952mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010040109920 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20247102 | 0.488%(0.4ml:1.952mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010040209920 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20247102 | 0.488%(0.4ml:1.952mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010040309920 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20247102 | 0.488%(0.4ml:1.952mg)(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010040409920 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20103148 | 0.488%(5ml:24.4mg,(以C18H20FN3O4计)) | Category A (甲) | XS01AEZ074G010050101442 | NHSA |
| 河北创健药业有限公司 | 国药准字H20113118 | 5ml:24.4mg(以左氧氟沙星计) | Category A (甲) | XS01AEZ074G010050102680 | NHSA |
| 中山万汉制药有限公司 | 国药准字H20203122 | 5ml:24.4mg(按C18H20FN3O4计) | Category A (甲) | XS01AEZ074G010050109920 | NHSA |
| 江苏广承药业有限公司 | 国药准字H20103148 | 0.488%(5ml:24.4mg,(以C18H20FN3O4计)) | Category A (甲) | XS01AEZ074G010060101442 | NHSA |
| 河北创健药业有限公司 | 国药准字H20113118 | 5ml:24.4mg(以左氧氟沙星计) | Category A (甲) | XS01AEZ074G010070102680 | NHSA |
| 河北合渡药业有限公司 | 国药准字H20255153 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010080102680 | NHSA |
| 石家庄凯达生物工程有限公司 | 国药准字H20255627 | 0.488%(5ml:24.4mg)(按C₁₈H₂₀FN₃O₄计) | Category A (甲) | XS01AEZ074G010090102680 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 16 filings and 13 distinct first applicants.
Generic 13 · Supplement 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 安徽省双科药业有限公司 | CYHS2602543 | Generic | 2026/10/14 | Not stated by source | CDE |
| 山东海山药业有限公司;山东威智百科药业有限公司 | CYHS2602399 | Generic | 2026/09/23 | Not stated by source | CDE |
| 西藏安星医药有限公司;四川禾亿制药有限公司 | CYHS2601996 | Generic | 2026/08/13 | Not stated by source | CDE |
| 西藏安星医药有限公司;四川禾亿制药有限公司 | CYHS2601995 | Generic | 2026/08/13 | Not stated by source | CDE |
| 山东禾琦制药有限公司;浙江赛默制药有限公司 | CYHS2601794 | Generic | 2026/07/27 | Not stated by source | CDE |
| 广东南国药业有限公司 | CYHB2601378 | Supplement | 2026/07/21 | Not stated by source | CDE |
| 黑龙江显东药业有限公司 | CYHS2601622 | Generic | 2026/07/07 | Not stated by source | CDE |
| 上海阿尔福斯医药科技有限公司;浙江赛默制药有限公司 | CYHB2601277 | Supplement | 2026/07/07 | Not stated by source | CDE |
| 长春迪瑞制药有限公司 | CYHS2600681 | Generic | 2026/03/19 | Not stated by source | CDE |
| 长春迪瑞制药有限公司 | CYHS2600680 | Generic | 2026/03/19 | Not stated by source | CDE |
| 长春迪瑞制药有限公司 | CYHS2600679 | Generic | 2026/03/19 | Not stated by source | CDE |
| 四川好医生攀西药业有限责任公司;合肥华威药业有限公司 | CYHS2600542 | Generic | 2026/02/26 | Not stated by source | CDE |
| 国药集团三益药业（芜湖）有限公司 | CYHS2504524 | Generic | 2026/01/04 | Not stated by source | CDE |
| 武汉五景药业有限公司 | CYHS2504307 | Generic | 2025/12/17 | Not stated by source | CDE |
| 成都普什制药有限公司 | CYHB2501931 | Supplement | 2025/09/28 | Not stated by source | CDE |
| 重庆药谷制药有限公司;北京汇恩兰德制药有限公司 | CYHS2502440 | Generic | 2025/07/09 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 11 filings and 8 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 安徽省双科药业有限公司 | CYHS2602543 | Generic | 2026/10/14 | Not stated by source | CDE |
| 山东海山药业有限公司;山东威智百科药业有限公司 | CYHS2602399 | Generic | 2026/09/23 | Not stated by source | CDE |
| 西藏安星医药有限公司;四川禾亿制药有限公司 | CYHS2601996 | Generic | 2026/08/13 | Not stated by source | CDE |
| 西藏安星医药有限公司;四川禾亿制药有限公司 | CYHS2601995 | Generic | 2026/08/13 | Not stated by source | CDE |
| 山东禾琦制药有限公司;浙江赛默制药有限公司 | CYHS2601794 | Generic | 2026/07/27 | Not stated by source | CDE |
| 黑龙江显东药业有限公司 | CYHS2601622 | Generic | 2026/07/07 | Not stated by source | CDE |
| 长春迪瑞制药有限公司 | CYHS2600681 | Generic | 2026/03/19 | Not stated by source | CDE |
| 长春迪瑞制药有限公司 | CYHS2600680 | Generic | 2026/03/19 | Not stated by source | CDE |
| 长春迪瑞制药有限公司 | CYHS2600679 | Generic | 2026/03/19 | Not stated by source | CDE |
| 四川好医生攀西药业有限责任公司;合肥华威药业有限公司 | CYHS2600542 | Generic | 2026/02/26 | Not stated by source | CDE |
| 国药集团三益药业（芜湖）有限公司 | CYHS2504524 | Generic | 2026/01/04 | Not stated by source | CDE |
API registrations
Non-component matches: 51 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 左氧氟沙星 | 浙江医药股份有限公司新昌制药厂 | Y20220001323 | A | Exact ingredient | 2025/09/28 | CDE |
| 左氧氟沙星 | QUIMICA SINTETICA S.A. | Y20220000523 | A | Exact ingredient | 2024/11/29 | CDE |
| 左氧氟沙星 | 浙江司太立制药股份有限公司 | Y20190009874 | A | Exact ingredient | 2023/06/22 | CDE |
| 盐酸左氧氟沙星 | 浙江东亚药业股份有限公司 | Y20190009849 | A | Salt-normalized ingredient | 2025/04/02 | CDE |
| 乳酸左氧氟沙星 | 绍兴京新药业有限公司 | Y20190009764 | A | Salt-normalized ingredient | 2026/01/13 | CDE |
| 左氧氟沙星 | 浙江东亚药业股份有限公司 | Y20190009576 | A | Exact ingredient | 2024/12/10 | CDE |
| 左氧氟沙星 | 浙江普洛康裕制药有限公司 | Y20190009507 | A | Exact ingredient | 2024/11/09 | CDE |
| 左氧氟沙星 | 浙江朗华制药有限公司 | Y20190009366 | A | Exact ingredient | 2024/10/12 | CDE |
| 左氧氟沙星 | 绍兴京新药业有限公司 | Y20190009344 | A | Exact ingredient | 2025/01/08 | CDE |
| 左氧氟沙星 | DAIICHI SANKYO CO.,LTD. | Y20190009123 | A | Exact ingredient | 2024/11/12 | CDE |
| 左氧氟沙星 | DAIICHI SANKYO CO., LTD. | Y20190009121 | A | Exact ingredient | 2024/11/12 | CDE |
| 盐酸左氧氟沙星 | 绍兴京新药业有限公司 | Y20190008943 | A | Salt-normalized ingredient | 2024/12/27 | CDE |
| 甲磺酸左氧氟沙星 | 广东逸舒制药股份有限公司 | Y20190008856 | A | Salt-normalized ingredient | — | CDE |
| 盐酸左氧氟沙星 | 河南康达制药有限公司 | Y20190007638 | A | Salt-normalized ingredient | 2024/07/20 | CDE |
| 左氧氟沙星 | 浙江昂利康制药股份有限公司 | Y20190007461 | A | Exact ingredient | 2024/02/05 | CDE |
| 左氧氟沙星 | 浙江国邦药业有限公司 | Y20190007451 | A | Exact ingredient | 2024/02/08 | CDE |
| 盐酸左氧氟沙星 | 浙江国邦药业有限公司 | Y20190007450 | A | Salt-normalized ingredient | 2024/02/08 | CDE |
| 甲磺酸左氧氟沙星 | 天方药业有限公司 | Y20190007440 | A | Salt-normalized ingredient | 2024/01/17 | CDE |
| 左氧氟沙星 | 河北智同生物制药股份有限公司 | Y20190007089 | A | Exact ingredient | 2024/03/05 | CDE |
| 乳酸左氧氟沙星 | 山西普德药业有限公司 | Y20190007045 | A | Salt-normalized ingredient | 2023/03/24 | CDE |
| 乳酸左氧氟沙星 | 湖北四环制药有限公司 | Y20190006942 | A | Salt-normalized ingredient | 2023/03/24 | CDE |
| 左氧氟沙星 | 四川仁安药业有限责任公司 | Y20190006790 | A | Exact ingredient | 2023/03/24 | CDE |
| 乳酸左氧氟沙星 | 天方药业有限公司 | Y20190006750 | A | Salt-normalized ingredient | 2025/08/22 | CDE |
| 甲磺酸左氧氟沙星 | 海南新世通制药有限公司 | Y20190006744 | A | Salt-normalized ingredient | — | CDE |
| 盐酸左氧氟沙星 | 天方药业有限公司 | Y20190006709 | A | Salt-normalized ingredient | 2025/08/22 | CDE |
| 乳酸左氧氟沙星 | 六安华源制药有限公司 | Y20190006541 | A | Salt-normalized ingredient | — | CDE |
| 甲磺酸左氧氟沙星 | 江陵奔达制药有限公司 | Y20190006510 | A | Salt-normalized ingredient | — | CDE |
| 盐酸左氧氟沙星 | 浙江司太立制药股份有限公司 | Y20190006264 | A | Salt-normalized ingredient | 2025/07/18 | CDE |
| 甲磺酸左氧氟沙星 | 浙江杭康药业有限公司 | Y20190006174 | A | Salt-normalized ingredient | — | CDE |
| 甲磺酸左氧氟沙星 | 海南葫芦娃药业集团股份有限公司 | Y20190006074 | A | Salt-normalized ingredient | 2024/07/11 | CDE |
| 甲磺酸左氧氟沙星 | 海南灵康制药有限公司 | Y20190006073 | A | Salt-normalized ingredient | 2024/07/12 | CDE |
| 甲磺酸左氧氟沙星 | 海南海灵化学制药有限公司 | Y20190005980 | A | Salt-normalized ingredient | 2025/06/11 | CDE |
| 甲磺酸左氧氟沙星 | 四川百利药业有限责任公司 | Y20190005950 | A | Salt-normalized ingredient | 2026/01/09 | CDE |
| 左氧氟沙星 | 重庆圣华曦药业股份有限公司 | Y20190005279 | A | Exact ingredient | 2025/09/18 | CDE |
| 盐酸左氧氟沙星 | 常州兰陵制药有限公司 | Y20190004985 | A | Salt-normalized ingredient | 2026/06/22 | CDE |
| 甲磺酸左氧氟沙星 | 湖北科益药业股份有限公司 | Y20190004725 | A | Salt-normalized ingredient | 2025/12/23 | CDE |
| 甲磺酸左氧氟沙星 | 湖北午时药业股份有限公司 | Y20190004724 | A | Salt-normalized ingredient | 2025/08/14 | CDE |
| 盐酸左氧氟沙星 | 苏州弘森药业股份有限公司 | Y20190004721 | A | Salt-normalized ingredient | 2025/08/14 | CDE |
| 盐酸左氧氟沙星 | 江苏恒瑞医药股份有限公司 | Y20190004686 | A | Salt-normalized ingredient | — | CDE |
| 乳酸左氧氟沙星 | 湖南中启制药有限公司岳阳分公司 | Y20190004649 | A | Salt-normalized ingredient | — | CDE |
| 甲磺酸左氧氟沙星 | 亚宝药业集团股份有限公司 | Y20190004613 | A | Salt-normalized ingredient | 2025/09/06 | CDE |
| 甲磺酸左氧氟沙星 | 开封制药（集团）有限公司 | Y20190004437 | A | Salt-normalized ingredient | 2024/11/01 | CDE |
| 甲磺酸左氧氟沙星 | 浙江浙北药业有限公司 | Y20190004320 | A | Salt-normalized ingredient | 2024/12/11 | CDE |
| 甲磺酸左氧氟沙星 | 海南中和药业股份有限公司 | Y20190004245 | A | Salt-normalized ingredient | 2024/07/11 | CDE |
| 盐酸左氧氟沙星 | 辽宁药联制药有限公司 | Y20190004150 | A | Salt-normalized ingredient | 2025/06/19 | CDE |
| 甲磺酸左氧氟沙星 | 晋城海斯制药有限公司 | Y20190003992 | A | Salt-normalized ingredient | 2025/05/29 | CDE |
| 乳酸左氧氟沙星 | 江西大地制药有限责任公司 | Y20190003958 | A | Salt-normalized ingredient | 2025/08/12 | CDE |
| 盐酸左氧氟沙星 | 江西大地制药有限责任公司 | Y20190003957 | A | Salt-normalized ingredient | 2025/08/12 | CDE |
| 甲磺酸左氧氟沙星 | 华润双鹤药业股份有限公司 | Y20190003928 | A | Salt-normalized ingredient | — | CDE |
| 甲磺酸左氧氟沙星 | 珠海润都制药股份有限公司 | Y20190002952 | A | Salt-normalized ingredient | 2026/06/23 | CDE |
| 盐酸左氧氟沙星 | 河南蓝图制药有限公司 | Y20190002907 | A | Salt-normalized ingredient | — | CDE |
| 盐酸左氧氟沙星 | 扬子江药业集团江苏海慈生物药业有限公司 | Y20190002697 | A | Salt-normalized ingredient | 2025/04/16 | CDE |
| 乳酸左氧氟沙星 | 浙江医药股份有限公司新昌制药厂 | Y20190002523 | A | Salt-normalized ingredient | 2026/01/13 | CDE |
| 盐酸左氧氟沙星 | 浙江医药股份有限公司新昌制药厂 | Y20190002497 | A | Salt-normalized ingredient | 2025/03/18 | CDE |
| 盐酸左氧氟沙星 | 浙江普洛康裕制药有限公司 | Y20190002276 | A | Salt-normalized ingredient | 2024/11/09 | CDE |
| 甲磺酸左氧氟沙星 | 浙江普洛康裕制药有限公司 | Y20190002247 | A | Salt-normalized ingredient | 2024/12/07 | CDE |
| 甲磺酸左氧氟沙星 | 辽源市百康药业有限责任公司 | Y20190002140 | A | Salt-normalized ingredient | 2025/03/26 | CDE |
| 盐酸左氧氟沙星 | 海南海灵化学制药有限公司 | Y20190001907 | A | Salt-normalized ingredient | 2024/07/11 | CDE |
| 乳酸左氧氟沙星 | 浙江先锋科技集团股份有限公司 | Y20190001767 | A | Salt-normalized ingredient | — | CDE |
| 甲磺酸左氧氟沙星 | 山西振东泰盛制药有限公司 | Y20190001742 | A | Salt-normalized ingredient | 2025/01/25 | CDE |
| 甲磺酸左氧氟沙星 | 山西普德药业有限公司 | Y20190001734 | A | Salt-normalized ingredient | 2025/02/14 | CDE |
| 盐酸左氧氟沙星 | 珠海联邦制药股份有限公司 | Y20190001635 | A | Salt-normalized ingredient | 2024/12/25 | CDE |
| 乳酸左氧氟沙星 | 上海中西三维药业有限公司 | Y20190001481 | A | Salt-normalized ingredient | 2025/01/27 | CDE |
| 盐酸左氧氟沙星 | 浙江朗华制药有限公司 | Y20190001466 | A | Salt-normalized ingredient | 2024/08/23 | CDE |
| 甲磺酸左氧氟沙星 | 浙江朗华制药有限公司 | Y20190001396 | A | Salt-normalized ingredient | 2024/10/22 | CDE |
| 乳酸左氧氟沙星 | 浙江朗华制药有限公司 | Y20190001395 | A | Salt-normalized ingredient | 2024/09/15 | CDE |
| 左氧氟沙星 | 浙江昌海制药有限公司 | Y20190000367 | A | Exact ingredient | 2023/07/28 | CDE |
| 左氧氟沙星（供注射用） | 浙江朗华制药有限公司 | Y20190000118 | A | Exact ingredient | 2026/05/20 | CDE |
| 左氧氟沙星 | 浙江朗华制药有限公司 | Y20180001384 | A | Exact ingredient | 2026/06/27 | CDE |
| 左氧氟沙星 | 浙江司太立制药股份有限公司 | Y20180001433 | A | Exact ingredient | 2026/07/17 | CDE |
| 左氧氟沙星 | 浙江东亚药业股份有限公司 | Y20170002036 | A | Exact ingredient | 2026/11/05 | CDE |
| 乳酸左氧氟沙星 | 绍兴京新药业有限公司 | Y20170001975 | A | Salt-normalized ingredient | 2022/10/12 | CDE |
| 左氧氟沙星 | 宜昌东阳光长江药业股份有限公司 | Y20170000195 | A | Exact ingredient | 2023/10/31 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/20Marketing application approved
盈科瑞（珠海金湾）制药有限公司
CYHS2500609 · 国药准字H20266303
Fact date: 2026/10/20 · Publication date: 2026/10/22 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 28 ↗ -
2026/10/14Accepted
-
2026/09/23Accepted
山东海山药业有限公司;山东威智百科药业有限公司
CYHS2602399
Fact date: 2026/09/23 · Site observation date: 2026/10/22
View source ↗ -
2026/08/13Accepted
西藏安星医药有限公司;四川禾亿制药有限公司
CYHS2601996
Fact date: 2026/08/13 · Site observation date: 2026/10/22
View source ↗ -
2026/08/13Accepted
西藏安星医药有限公司;四川禾亿制药有限公司
CYHS2601995
Fact date: 2026/08/13 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Levofloxacin Eye Drops
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy